Guideline care first
Guideline-directed therapy saves lives
Cause-specific medicines, devices, revascularization where indicated, congestion management, rehabilitation, and advanced-heart-failure referral remain central to every plan we coordinate.
A cardiac plan matched to your phenotype
Stem cell therapy for heart failure in Istanbul
Our Istanbul cardiology team pairs guideline-directed heart-failure care with catheter-based cell protocols, precise dosing, and full monitoring throughout your stay.
Conceptual biological visualization
Evidence status
What the evidence can support now
Our catheter-based protocols
Catheter-delivered cell products
We work with defined marrow-derived or mesenchymal precursor products delivered into myocardium, typically for selected stable HFrEF patients under close monitoring.
What we won't promise
No claim of a fully regrown heart
We won't claim a generic IV MSC infusion replaces scar or removes the need for medication and devices. We're honest about what today's protocols can support.
A direct answer
The short answer
Our Istanbul cardiology team builds your heart-failure plan around guideline-directed therapy first, then adds catheter-delivered cell protocols matched to your phenotype, cause, and severity — with cardiologist oversight at every stage.
Start with the phenotype
Your heart-failure profile shapes your plan
Ejection fraction, cause, congestion, rhythm, valves, kidney function, and functional class all shape which protocol our cardiology team recommends for you.
We optimize the heart-failure pathway first
Every plan we build sits alongside therapies proven to reduce symptoms, hospitalization, and mortality — never in place of them.
- Confirm cause, ejection fraction, volume status, rhythm, valves, ischemia, and functional class
- Optimize guideline-directed medicines at tolerated doses with kidney and electrolyte monitoring
- Use cardiac resynchronization, defibrillator, valve, or revascularization therapy when indicated
- Manage congestion, exercise, nutrition, sleep apnea, diabetes, kidney disease, anemia, and blood pressure
- Refer early for LVAD, transplant, advanced-care, or palliative assessment when appropriate
- 01
HFrEF
Reduced ejection fraction has a strong evidence-based medication and device pathway and contains most major cell-therapy trial experience.
- 02
HFpEF and HFmrEF
Preserved or mildly reduced ejection fraction involves different phenotypes, comorbidities, and evidence.
- 03
Ischemic cardiomyopathy
Prior myocardial infarction, residual ischemia, scar burden, and revascularization status affect both standard care and research design.
- 04
Advanced heart failure
Repeated admissions, low output, inotrope dependence, organ dysfunction, LVAD, transplant, or palliative needs require specialist triage.
Product and route matter
Delivery method, matched to your case
Transendocardial injection, intracoronary delivery, direct surgical injection, and IV infusion involve different biology and procedural risk, and we select the right one for you.
- 01
Transendocardial mesenchymal precursor cells
A catheter maps the ventricle and injects a defined allogeneic product into selected myocardial regions.
Evidence boundaryThis is an invasive cardiac procedure, and the phase 3 DREAM-HF primary endpoint was neutral.
- 02
Autologous marrow-derived cells
Trials use selected or prepared cells from the patient's marrow with catheter delivery into the heart.
Evidence boundaryHarvest quality, cell composition, scar pattern, and trial endpoint vary substantially.
- 03
Intracoronary or IV products
Other protocols deliver cells through coronary arteries or the systemic circulation.
Evidence boundaryEvidence from myocardial injection cannot be transferred to an IV infusion, and arterial delivery adds vascular risk.
- 04
Engineered cardiac tissue
Laboratory research explores cardiomyocytes, patches, organoids, and tissue engineering.
Evidence boundaryArrhythmia, integration, blood supply, immune rejection, and scale remain major translational challenges.
Indexed evidence ledger
The evidence behind our protocols
We read every trial's primary outcome — not just an exploratory subgroup or a single ejection-fraction change — before recommending a protocol to you.
01 DREAM-HF phase 3
Open study- Product
- Transendocardial allogeneic mesenchymal precursor cells
- Study design
- Randomized double-blind sham-controlled study, 565 people with HFrEF
- Finding
- The primary recurrent heart-failure event endpoint and hierarchical secondary endpoints were neutral.
- Limitation
- Exploratory cardiovascular and inflammation-subgroup signals require confirmation and do not validate generic IV MSCs.
02 CHART-1
Open study- Product
- Autologous lineage-directed cardiopoietic cells
- Study design
- Randomized double-blind sham-controlled trial, 315 participants randomized
- Finding
- The prespecified hierarchical primary efficacy endpoint was neutral at 39 weeks.
- Limitation
- Post hoc subgroup or remodeling analyses cannot replace the neutral overall primary result.
03 CONCERT-HF phase 2
Open study- Product
- Autologous MSCs, c-kit-positive cardiac cells, their combination, or placebo
- Study design
- Randomized double-blind placebo-controlled four-arm study, 125 participants
- Finding
- Reported selected major-event and quality-of-life signals across different cell arms.
- Limitation
- Small multiple-arm exploratory study, not definitive proof of mortality, hospitalization, ventricular recovery, or a class effect.
Measure what changes
We measure what matters to you
Your plan follows clinical events and real-world function, not just an isolated ejection-fraction image or an early feeling after a procedure.
- 01
Clinical events
Heart-failure admissions, urgent IV treatment, arrhythmia, myocardial infarction, stroke, LVAD, transplant, and death.
- 02
Function and symptoms
NYHA class, six-minute walk, exercise testing, Kansas City Cardiomyopathy Questionnaire, congestion, and daily activity.
- 03
Cardiac structure
Standardized echocardiography or MRI for ejection fraction, volumes, valves, scar, and remodeling.
- 04
Procedure and organ safety
Arrhythmia, perforation, bleeding, vascular injury, infection, kidney injury, immune reaction, and hospitalization.
Clinical review before travel
Your free Istanbul medical evaluation
Send us your cardiology records, and our heart-failure specialists confirm medical stability, phenotype, and whether international travel and a catheter-based protocol are right for you.
Records to send
- Cardiology summary, cause, NYHA class, admission timeline, and blood-pressure or weight log
- Recent echocardiogram, cardiac MRI, coronary angiography, stress, valve, and rhythm reports
- Medication doses, tolerance, adherence, diuretic plan, implanted-device data, and revascularization history
- CBC, kidney, liver, electrolytes, natriuretic peptide, diabetes, and iron studies when relevant
- Six-minute walk, quality-of-life assessment, pulmonary testing, and advanced-heart-failure evaluation
Reasons to pause
- Worsening breathlessness at rest, chest pain, fainting, shock, rapid fluid gain, or another emergency symptom
- Decompensated heart failure, active ischemia, unstable rhythm, infection, clot, bleeding, or severe organ dysfunction
- An unresolved indication for revascularization, valve intervention, device therapy, LVAD, or transplant
- Any proposal to stop guideline-directed medication or call an IV infusion cardiac regeneration
Transparent planning
Heart failure stem cell therapy cost in Istanbul
An MSC protocol and a transendocardial catheter procedure are priced as distinct services. Your quote names the product, delivery system, catheter laboratory, anesthesia, cardiac monitoring, and follow-up, plus travel and hotel support.
Our 2026 MSC program planning range starts from $7,000-$18,000, giving you a transparent baseline confirmed exactly after your free evaluation.
- Heart-failure, imaging, rhythm, anesthesia, and interventional review
- Exact product, harvest, manufacturing, dose, route, and release testing
- Catheter laboratory, mapping, monitoring, hospitalization, and complication support
- Medication coordination, imaging, functional outcomes, and long-term follow-up
Questions patients ask before booking
- 01
Which heart-failure phenotype, cause, and delivery route match my case?
- 02
What does the program cost, and how many days will I spend in Istanbul?
- 03
What arrhythmia, perforation, vascular, bleeding, and anesthesia risks apply to my case?
- 04
How will you coordinate guideline therapy, devices, admissions, and long-term safety?
Primary reading
Sources behind this guide
FAQ
Questions about heart failure
Our 2026 MSC program planning range starts from $7,000, with catheter-based protocols priced separately based on delivery method and hospital needs. Your free evaluation confirms an exact quote.
Request Medical Evaluation
Begin a personalized treatment conversation with our medical team.
Share your case in confidence. Our international coordinators review every enquiry and respond within 24 hours, in your language.